Viral BCL-2 homologs (BHRF1 and E1B 19K) (vBcl-2)

BHRF1 and E1B 19K are viral homologs of the human BCL-2 family of anti-apoptotic proteins, encoded by the Epstein-Barr virus (EBV) and Adenovirus, respectively (UniProt P03182, P03247). These proteins play a critical role in the viral lifecycle by preventing premature host cell death (apoptosis) during infection, thereby maximizing viral progeny production (PubMed 31645677). BHRF1 is particularly significant in EBV-associated malignancies, such as Burkitt lymphoma and nasopharyngeal carcinoma, where it contributes to lymphomagenesis and confers resistance to chemotherapy by sequestering pro-apoptotic host proteins like BIM, PUMA, and BAK (PubMed 21203485). E1B 19K similarly blocks apoptosis induced by viral E1A or external stimuli like TNF-alpha by interacting with BAK and BAX (PubMed 8600029). Due to their role in promoting the survival of infected and cancerous cells, these viral BCL-2 homologs are attractive therapeutic targets for virus-associated cancers and for enhancing oncolytic viral therapies. While they often show resistance to clinical BH3-mimetics like venetoclax, novel specific inhibitors such as the computationally designed protein BINDI have shown promise in selectively inducing apoptosis in EBV-positive cancer cells (PubMed 24949971).

Other names

BHRF1E1B 19KApoptosis regulator BHRF1Adenovirus E1B 19,000-molecular-weight proteinBamHI rightward reading frame 1Early antigen protein R (EA-R)vBcl-2

Direct binding and sequestration of pro-apoptotic BH3-only proteins (e.g., BIM, PUMA) and executioner proteins (e.g., BAK, BAX) to prevent mitochondrial outer membrane permeabilization (MOMP).